Organon Puts A Name On Its Supply Problem, Pegging The Third-Quarter Revenue Hit At Under 2%

Four established brands now carry the "Supply Constraints" label as full recovery of the supply chains is still ongoing, the company says.

Share
Organon Puts A Name On Its Supply Problem, Pegging The Third-Quarter Revenue Hit At Under 2%

Organon, the prescription-medicine maker, now attributes part of its revenue slide to a defined set of "Supply Constraints," which it estimates cost approximately less than 2% of consolidated revenue in the third quarter, according to its quarterly report filed Friday. The term is new: the prior report blamed only temporary supply limits in Japan for Singulair.

A cluster of problems gets a label

The label covers four things: a key contract manufacturer's production disruptions, temporary limits at certain facilities, a labor dispute at a third-party logistics provider, and geopolitical disruption. Management says mitigation is under way; some problems are fixed, but the supply chains have not fully recovered.

The filing ties the constraints to Atozet, Zetia/Vytorin, Nasonex and Arcoxia. Atozet sales fell 10% in the quarter to $85 million, helped down by European pricing as well. Arcoxia sales slipped 3% to $69 million on the constraints and weaker demand in Mexico; the second-quarter report had shown the brand up 11%.

The constraints also cut into the nine-month tallies for Zetia/Vytorin and Nasonex, and Dulera's 5% third-quarter rise is attributed to recovery from constraints that hit it in the third quarter of 2025.

Nexplanon sags, and an offset disappears

Nexplanon, the contraceptive implant, fell 10% in the quarter to $200 million as physician demand in the United States weakened after the five-year label approval, with reinsertions delayed and uncertainty over federal funding. The prior filing's estimate that expanded use from the new label would begin offsetting the reinsertion drag in the second half of 2026 no longer appears.

Total revenue was $1,574 million, down 2% from $1,602 million. Diluted earnings per share edged to $0.60 from $0.61 because diluted shares rose to 272,384 thousand from 260,653 thousand; net income rose to $164 million from $160 million.

A pending buyout and a bigger Samsung bill

Organon, which sells more than 70 products in women's health and general medicines, agreed in April to be bought by Sun Pharma for $14.00 per share in cash, and stockholders approved the deal on July 23. Closing is now targeted by early 2027.

Payables to Samsung Bioepis within trade accounts payable stood at $188 million at September 30, 2026, against $94 million at December 31, 2025. The two companies amended their biosimilar agreement on September 11 to add dosage forms of Pyzchiva in Canada, where the product launched in the third quarter.

The next marker is the closing of the Sun Pharma deal, which the company expects by early 2027.

Sources